Evidence map›Paper›PMID 37030524›Full record

ArticleClinical immunology (Orlando, Fla.)2023

Reduced quantity and function of pneumococcal antibodies are associated with exacerbations of COPD in SPIROMICS.

David C LaFon, Han Woo, Neal Fedarko, Antoine Azar, Harry Hill, Anne E Tebo, Thomas B Martins, MeiLan K Han, Jerry A Krishnan, Victor E Ortega and 12 more

Registry-linked trialOpen access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical immunology (Orlando, Fla.), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01969344 (Subpopulations and Intermediate Outcome Measures in COPD Study), which is not on this map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.9field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01969344 active not recruitingnot on this map

Subpopulations and Intermediate Outcome Measures in COPD Study

TypeobservationalSponsorUniversity of North Carolina, Chapel HillRan2010 to 2031Enrolled2,981ConditionsCOPD, Chronic Obstructive Pulmonary Disease, Chronic Bronchitis, Emphysema
3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 4 citations in OpenAlex.

  1. Observational
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors at 11 institutions in 1 country.

David C LaFonDivision of Pulmonary, Allergy, and Critical Care Medicine, University of Alabama at Birmingham Heersink School of Medicine, Birmingham, AL, United States; UAB Lung Health Center, Birmingham, AL, United States. Electronic address: dlafon@uabmc.edu.
Han WooJohns Hopkins University, Baltimore, MD, United States.
Neal FedarkoJohns Hopkins University, Baltimore, MD, United States.
Antoine AzarJohns Hopkins University, Baltimore, MD, United States.
Harry HillDepartment of Pathology, University of Utah Health and ARUP Laboratories, Salt Lake City, UT, United States.
Anne E TeboDepartment of Pathology, University of Utah Health and ARUP Laboratories, Salt Lake City, UT, United States; Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, United States.
Thomas B MartinsDepartment of Pathology, University of Utah Health and ARUP Laboratories, Salt Lake City, UT, United States.
MeiLan K HanPulmonary and Critical Care Medicine, University of Michigan, Ann Arbor, MI, United States.
Jerry A KrishnanUniversity of Illinois, Chicago, IL, United States.
Victor E OrtegaMayo Clinic, Scottsdale, AZ, United States.
Igor BarjaktarevicPulmonary and Critical Care, University of California Los Angeles, Los Angeles, CA, United States.
Robert J KanerWeill Cornell Medicine, New York, NY, United States.
Annette HastieWake Forest University School of Medicine, Winston-Salem, NC, United States.
Wanda K O'NealMarisco Lung Institute, University of North Carolina School of Medicine, Chapel Hill, NC, United States.
David CouperUniversity of North Carolina Department of Biostatistics, Chapel Hill, NC, United States.
Prescott G WoodruffUniversity of California, San Francisco, CA, United States.
Jeffrey L CurtisPulmonary and Critical Care Medicine, University of Michigan, Ann Arbor, MI, United States; VA Ann Arbor Healthcare System, Ann Arbor, MI, United States.
Nadia N HanselJohns Hopkins University, Baltimore, MD, United States.
Moon H NahmDivision of Pulmonary, Allergy, and Critical Care Medicine, University of Alabama at Birmingham Heersink School of Medicine, Birmingham, AL, United States; Department of Microbiology, University of Alabama at Birmingham, United States.
Mark T DransfieldDivision of Pulmonary, Allergy, and Critical Care Medicine, University of Alabama at Birmingham Heersink School of Medicine, Birmingham, AL, United States; UAB Lung Health Center, Birmingham, AL, United States; Birmingham VA Medical Center, Birmingham, AL, United States.
Nirupama PutchaJohns Hopkins University, Baltimore, MD, United States.
SPIROMICS investigators
Johns Hopkins University · USUniversity of Alabama at Birmingham · USUniversity of Utah · USUniversity of Michigan · USUniversity of North Carolina at Chapel Hill · USCornell University · USMayo Clinic in Arizona · USUniversity of California, Los Angeles · USUniversity of California, San Francisco · USUniversity of Illinois Chicago · USWake Forest University · US

Funding

Institute for Clinical and Translational ResearchUL1TR001079 · NCATS · JOHNS HOPKINS UNIVERSITY · PI FORD, DANIEL ERNEST · 2013 to 2017
$60.1M
SPIROMICS II: Biological underpinnings of COPD heterogeneity and progressionU01HL137880 · NHLBI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI WOODRUFF, PRESCOTT G · 2017 to 2021
$27.9M
SPIROMICS GIC SupportU24HL141762 · NHLBI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI COUPER, DAVID J, O'NEAL, WANDA K · 2018 to 2022
$7.2M
Training Program in Lung Biology and Translational MedicineT32HL105346 · NHLBI · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI GAGGAR, AMIT · 2010 to 2025
$5.0M
The association of allergic disease with clinical outcomes in COPD.K23HL123594 · NHLBI · JOHNS HOPKINS UNIVERSITY · PI PUTCHA, NIRUPAMA · 2015 to 2019
$1.0M
Impaired Pneumococcal Antibody Function and Exacerbations of Chronic Obstructive Pulmonary DiseaseK08HL157651 · NHLBI · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI David Cardy LaFon · 2022 to 2026
$804k
UAB Mentoring Program in COPD Patient Oriented ResearchK24HL140108 · NHLBI · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI DRANSFIELD, MARK T · 2018 to 2022
$439k
NCATS NIH HHS UL1 TR001079NHLBI NIH HHS HHSN268200900013CNHLBI NIH HHS HHSN268200900014CNHLBI NIH HHS HHSN268200900015CNHLBI NIH HHS HHSN268200900016CNHLBI NIH HHS HHSN268200900017CNHLBI NIH HHS HHSN268200900018CNHLBI NIH HHS HHSN268200900019CNHLBI NIH HHS HHSN268200900020CNHLBI NIH HHS K08 HL157651NHLBI NIH HHS K23 HL123594NHLBI NIH HHS K24 HL140108NHLBI NIH HHS T32 HL105346NHLBI NIH HHS U01 HL137880NHLBI NIH HHS U24 HL141762
6 · The paper itself

Abstract

While hypogammaglobulinemia is associated with COPD exacerbations, it is unknown whether frequent exacerbators have specific defects in antibody production/function. We hypothesized that reduced quantity/function of serum pneumococcal antibodies correlate with exacerbation risk in the SPIROMICS cohort. We measured total pneumococcal IgG in n = 764 previously vaccinated participants with COPD. In a propensity-matched subset of n = 200 with vaccination within five years (n = 50 without exacerbations in the previous year; n = 75 with one, n = 75 with ≥2), we measured pneumococcal IgG for 23 individual serotypes, and pneumococcal antibody function for 4 serotypes. Higher total pneumococcal IgG, serotype-specific IgG (17/23 serotypes), and antibody function (3/4 serotypes) were independently associated with fewer prior exacerbations. Higher pneumococcal IgG (5/23 serotypes) predicted lower exacerbation risk in the following year. Pneumococcal antibodies are inversely associated with exacerbations, supporting the presence of immune defects in frequent exacerbators. With further study, pneumococcal antibodies may be useful biomarkers for immune dysfunction in COPD.

Indexed as

Pneumococcal InfectionsPulmonary Disease, Chronic ObstructiveAntibodies, BacterialHumansImmunoglobulin GImmunologic TestsPneumococcal VaccinesStreptococcus pneumoniaeVaccinationAntibodies, BacterialImmunoglobulin GPneumococcal VaccinesAntibodiesImmunityImmunoglobulin GOpsonizationStreptococcus pneumoniae

Identifiers

PMID37030524
PMCPMC10171244
OpenAlexW4362673361

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.